The effects of nandrolone, testosterone and their decanoate esters on murine lupus.
Treatment of NZB/NZW F1 (B/W) female and castrated male mice with testosterone or 19-nortestosterone (nandrolone), either by implantation in silastic tubing or by subcutaneous injections of their decanoate esters, reduced in a dose-dependent manner symptoms associated with murine lupus (proteinuria, IgG antibodies to DNA) and prolonged survival. These phenomena were observed under both prophylactic (start at 3-4 weeks) and therapeutic treatments (start 27-29 weeks). Nandrolone and its decanoate ester were at least as potent as testosterone and testosterone decanoate. As the unwanted androgenic properties of nandrolone and its ester are significantly less pronounced than those of testosterone and its ester, also in these NZB/NZW mice, the beneficial effect on murine lupus does not seem to be associated with these properties.
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D002369:Castration; D004247:DNA / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D051379:Mice; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use*; D009929:Organ Size / Q000187:drug effects; D011507:Proteinuria / Q000188:drug therapy; D013739:Testosterone / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000974:Antibodies, Antinuclear; D013739:Testosterone; D009277:Nandrolone; D004247:DNA